MiNK Therapeutics (NASDAQ:INKT) Posts Quarterly Earnings Results, Beats Expectations By $0.20 EPS

MiNK Therapeutics (NASDAQ:INKT) posted its quarterly earnings results on Friday. The company reported ($0.57) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.77) by $0.20, Zacks reports.

Here are the key takeaways from MiNK Therapeutics’ conference call:

• MiNK said its AGENT-797 iNKT platform continues to show encouraging signals across oncology and critical illness, including durable survival in refractory gastric cancer and immune modulation in ARDS and lung injury.
• The company initiated a randomized phase II ARDS trial of AGENT-797 versus placebo on top of standard of care, with a planned seamless phase II/III design and FDA discussions expected in the coming weeks.
• Management highlighted translational data showing the same donor-derived product can generate different immune responses depending on disease state, supporting a potential biomarker-driven approach for patient selection in ARDS.
• MiNK’s cash position of about $9.5 million at quarter-end, plus operational efficiencies and non-dilutive collaboration support, is expected to fund at least the next 12 months of operations, including the randomized trial launch.
• The company also expanded its pipeline and partnership strategy through a C-Further collaboration for a PRAME-targeted TCR-engineered iNKT program in pediatric cancers and said it will present additional data, including an ANKTIVA combination study, at upcoming medical meetings.

MiNK Therapeutics Stock Up 2.0%

NASDAQ INKT traded up $0.21 during trading hours on Friday, hitting $10.72. The company had a trading volume of 36,280 shares, compared to its average volume of 39,440. MiNK Therapeutics has a fifty-two week low of $6.65 and a fifty-two week high of $76.00. The business has a fifty day simple moving average of $11.00 and a 200-day simple moving average of $11.61. The firm has a market cap of $53.39 million, a P/E ratio of -3.77 and a beta of 0.47.

Analyst Ratings Changes

Several analysts have weighed in on INKT shares. Wall Street Zen upgraded shares of MiNK Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday. HC Wainwright reaffirmed a “buy” rating and issued a $35.00 price target on shares of MiNK Therapeutics in a report on Wednesday, April 1st. Finally, Weiss Ratings downgraded shares of MiNK Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, MiNK Therapeutics has an average rating of “Hold” and a consensus target price of $35.00.

Hedge Funds Weigh In On MiNK Therapeutics

An institutional investor recently raised its position in MiNK Therapeutics stock. Geode Capital Management LLC raised its position in shares of MiNK Therapeutics, Inc. (NASDAQ:INKT) by 11.3% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 14,247 shares of the company’s stock after purchasing an additional 1,441 shares during the period. Geode Capital Management LLC owned 0.30% of MiNK Therapeutics worth $159,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 2.87% of the company’s stock.

About MiNK Therapeutics

MiNK Therapeutics, Inc is a clinical-stage biotechnology company developing exosome-based immunotherapies for the treatment of solid tumors. The company’s proprietary platform isolates and engineers naturally occurring extracellular vesicles, or exosomes, to deliver therapeutic payloads—such as mRNA, proteins and modulatory factors—directly into the tumor microenvironment. By leveraging the innate cell‐to‐cell communication properties of exosomes, MiNK aims to reprogram immune cells and overcome immune suppression within solid tumors.

MiNK’s preclinical pipeline features multiple lead candidates designed to repolarize tumor‐associated macrophages and boost T cell–mediated tumor clearance.